Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations.
Seventy-one patients with neuroblastoma (NB) and 25 patients with other neoplastic or nonneoplastic diseases were studied with MIBG scintigraphy. Sensitivity and specificity at diagnosis were 94% and 88%, respectively. Of 52 patients with NB studied during follow-up, 14 had on one or several occasions conflicting results, when the findings at MIBG scintigraphy were compared to standard investigations (SI: CT scan, bone scan, x-ray, and ultrasound). The correlation of MIBG scintigraphy and SI to clinical outcome were in these 14 patients not significantly different. Adding VMA-excretion measurements did not significantly improve the predictive value of MIBG scintigraphy or SI. Patients with tumor-suspected lesions only at MIBG scintigraphy should be followed closely and the nature of the lesions should be explored through biopsy.
Schmiegelow
K
K
Nordic Society of Paediatric Hematology and Oncology (NOPHO).
Simes
M A
MA
Agertoft
L
L
Berglund
G
G
Storm-Mathisen
I
I
Andreassen
M
M
Salmi
T T
TT
Nygård
R
R
Wiebe
T
T
Kreuger
A
A
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008297:Male; D009447:Neuroblastoma / Q000000981:diagnostic imaging*; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D013565:Sympatholytics; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography; D014642:Vanilmandelic Acid / Q000652:urine
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013565:Sympatholytics; D019797:3-Iodobenzylguanidine; D014642:Vanilmandelic Acid